Inhibition of opioid-degrading enzymes potentiates Δ9- tetrahydrocannabinol-induced antinociception in mice

Neuropharmacology

Volumn 37, Issue 2, 1998, Pages 215-222

  Reche, Ignacio ^a   Ruiz Gayo, Mariano ^a   Fuentes, José A ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

9 Tetrahydrocannabinol; Antinociception; Bestatin; Endogenous enkephalins; Pain; SR 141,716 A, Thiorphan

Indexed keywords

AMINOPEPTIDASE; ANANDAMIDE; BESTATIN; BETA FUNALTREXAMINE; BINALTORPHIMINE; ENKEPHALIN; NALOXONE; OPIATE; PROTEINASE; RIMONABANT; TETRAHYDROCANNABINOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; DATA ANALYSIS; DEPRESSION; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; HYPOTENSION; HYPOTHERMIA; INTESTINE MOTILITY; MALE; MOUSE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING;

AMINOPEPTIDASES; ANIMALS; INJECTIONS, INTRAVENTRICULAR; LEUCINE; MALE; MICE; NARCOTIC ANTAGONISTS; NEPRILYSIN; PAIN THRESHOLD; PROTEASE INHIBITORS; TETRAHYDROCANNABINOL; THIORPHAN;

EID: 0032004188     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(98)00005-7     Document Type: Article

References (39)

1. Baamonde A., Daugé V., Gacel G., Roques B.P. Systemic administration of (Tyr-D-Ser(O-tertbutyl)-Gly-Phe-Leu-Thr(O-tertbutyl), a highly selective delta opioid agonist induces mu receptor-mediated analgesia in mice. J. Pharmacol. Exp. Ther. 257:1991;767-773.
2. Chakrabarti A., Onaivi E.S., Chaudhuri G. Cloning and sequencing of cDNA encoding the mouse brain-type cannabinoid receptor protein. DNA Seq. 5:1995;385-388.
3. Chu T.G., Orlowski M.M. Active site directed N-Carboxy-methyl-peptide inhibitors of a soluble metallopeptidase from rat brain. Mol. Pharmacol. 44:1984;8-12.
4. Compton D.R., Aceto M.D., Lowe J., Martin B.R. In vivo characterization of a specific cannabinoid receptor antagonist (SR-141,716-A): inhibition of delta-9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. 277:1996;586-594.
5. D'Amour F.E., Smith D.L. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72:1941;74-79.
6. Devane W.A., Dysarz III F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
7. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
8. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., Pomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 372:1994;686-691.
9. Eddy N.B., Liembach D. Synthetic analgesic (II): diethylbutenyl and dithienylbutylamines. J. Pharmacol. Exp. Ther. 107:1953;385-393.
10. Fournié-Zaluski M.C., Chaillet P., Bouboutou R., Coulaud A., Cherot P., Waksman G., Costentin J., Roques B.R. Analgesic effects of kelatorphan a new highly potent inhibitor of multiple enkephalin degrading enzymes. Eur. J. Pharmacol. 102:1984;525-528.
11. Gardner E.L., Lowinson J.H. Marijuanas interaction with brain reward system: Update 1991. Pharmacol. Biochem. Behav. 40:1991;571-580.
12. 5) enkephalin in brain slices using peptidase inhibitors and anti-aminopeptidase M antibodies. Mol. Pharmacol. 29:1986;281-287.
13. Haley T.J., McCormick W.G. Pharmacological effects produced by intracerebral injections of drugs in the conscious mouse. Br. J. Pharmacol. 12:1957;12-15.
14. Hylden J.L.K., Wilcox G.L. Intrathecal morphine in mice: a new technique. Eur. J. Pharmacol. 67:1980;313-316.
15. Lichtman A.H., Cook S.A., Martin B.R. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal grey involvement. J. Pharmacol. Exp. Ther. 276:1996;585-593.
16. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96:1949;99-113.
17. Llorens-Cortés C., Gros C., Schwartz J.C., Clot A.M., Le Bars D. Changes ion levels of the tripeptide Tyr-Gly-Gly as an index of enkephalin release in the spinal cord: Effects of noxious stimuli and parenterally-active peptidase inhibitors. Peptides. 10:1989;609-614.
18. Lord J.A.H., Waterfield A.A, Hughes J., Kosterlitz H.W. Endogenous opioid peptides: multiple agonists and receptors. Nature. 267:1977;495-499.
19. Mason, D.J., Welch, S.P., 1996. Delta-9-THC induces increases in spinal dynorphin A (1-17) and leucine enkephalin. International Cannabinoid Research Society. Abstracts of the 1996 Symposium on Cannabis and the Cannabinoids, p. 9.
20. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
21. McLaughlin C.R., Abood M.E. Developmental expression of cannbinoid receptor mRNA. Dev. Brain Res. 76:1993;75-78.
22. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
23. Noble F., Soleilhac J.M., Soroca-Lucas E., Turcaud S., Fournié-Zaluski M.C., Roques B.P. Inhibition of the enkephalin metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB101 induces potent analgesic responses in mice and rats. J. Pharmacol. Exp. Ther. 261:1992;181-190.
24. Otero M.J., Iglesias T., Fuentes J.A. Hypoalgesic action of bestatin analogues that inhibit central aminopeptidases but not neutral endopeptidase. Neuropeptides. 24:1993;17-182.
25. Pertwee R., Griffin G., Fernando S., Li X., Hill A., Makriyannis A. AM630 a competitive cannabinoid receptor antagonist. Life Sci. 56:1995;1949-1956.
26. Pugh G.J., Abood M.E., Welch S.P. Antisense oligodeoxynucleotides to the kappa-1 receptor block the antinociceptive effects of delta-9-THC in the spinal cord. Brain Res. 689:1995;157-158.
27. 9-terahydrocannabinol and morphine in spinal cord. J. Pharmacol. Exp. Ther. 279:1996;608-616.
28. Reche I., Fuentes J.A., Ruiz-Gayo M. A role for central cannabinoid and opioid systems in peripheral (9-tetrahydrocannabinol-induced analgesia in mice. Eur. J. Pharmacol. 301:1996;75-81.
29. 9-tetrahydrocannabinol-induced analgesia by morphine in mice: Involvement of μ- and δ-opioid receptors. Eur. J. Pharmacol. 318:1996;11-16.
30. Rinaldi-Carmona M., Barth F., Michel-Héaulme M., Shire D., Calandra B., Congy C., Martínez S., Maruani J., Néliat G., Caput D., Ferrara P., Soubrié P., Brelire J.C., Le Fur G. SR-141,716-A a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
31. Roques B.P., Fournié-Zaluski M.C., Soroca E. et al. The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature. 288:1980;286-288.
32. Rodhan A.L., Chipkin R., Yaksh T.L. The antinociceptive effects of SCH-32615, a neutral endopeptidase (enkephalinase) inhibitor, microinjected into the periaqueductal gray ventral medulla and amygdala. Brain Res. 520:1990;123-130.
33. 3H]diprenorphine binding. Brain Res. 571:1992;306-312.
34. Safavi A., Hertz B.H. Degradation of dynorphin-related peptides by the puromycin-sensitive aminopeptidase and aminopeptidase M. J. Neurochem. 65:1995;389-395.
35. 9-THC-DMH. J. Pharmacol. Exp. Ther. 263:1992;1383-1390.
36. Welch S.P. Blockade of cannabinoid induced antinociception by binaltorphimine, but not N,N-diallyltyrosine-Aib-Phenylalanine-leucine, ICI 174864 or naloxone in mice. J. Pharmacol. Exp. Ther. 265:1993;633-640.
37. Welch S.P., Stevens D.L. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine in mice. J. Pharmacol. Exp. Ther. 262:1992;10-17.
38. Welch S.P., Thomas C., Patrick G.S. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice. Possible mechanisms for interaction with morphine. J. Pharmacol. Exp. Ther. 272:1995;310-321.
39. Young E.A., Walker J.M., Houghten R., Akil H. The degradation of dynorphin A in the brain in vivo and in vitro. Peptides. 8:1987;701-707.